Calcyphosine 2/CAPS2 Polyclonal Antibody, FITC Conjugated

Applications

  • IF(IHC-P)
  • IF(IHC-F)
  • IF(ICC)

Predicted Reactivity

  • Human
  • Mouse
  • Rat
  • Cow
  • Sheep
  • Pig
  • Chicken
Overview
Catalog # bs-12163R-FITC
Product Name Calcyphosine 2/CAPS2 Polyclonal Antibody, FITC Conjugated
Applications IF(IHC-P), IF(IHC-F), IF(ICC)
Predicted Reactivity Human, Mouse, Rat, Cow, Sheep, Pig, Chicken
Specifications
Conjugation FITC
Host Rabbit
Source KLH conjugated synthetic peptide derived from human Calcyphosine 2/CAPS2
Immunogen Range 221-320/557
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide.
Storage Condition Store at 4°C for 12 months.
Target
Subcellular location Cell membrane
Synonyms Calcyphosin 2; Calcyphosin-2; Calcyphosine-2; Calcyphosine2; Calcyphosphine 2; CAPS 2; CAPS2; CAYP2_HUMAN; D630005B03Rik; FLJ34520; OTTHUMP00000202412; OTTMUSP00000027695; UG0636c06.
Background CAPS2 is a 557 amino acid calcium-binding protein that is abundantly expressed, with highest expression found in placenta, testis, colon, lung and brain. CAPS2 contains three EF-hand domains and exists as three alternatively spliced isoforms. Suggested to play a role in large dense-core vesicle (LDCV) exocytosis, CAPS2 is encoded by a gene that maps to human chromosome 12, which encodes over 1,100 genes and comprises approximately 4.5% of the human genome. Chromosome 12 is associated with a variety of diseases and afflictions, including hypochondrogenesis, achondrogenesis, Kniest dysplasia, Noonan syndrome and trisomy 12p, which causes facial developmental defects and seizure disorders.
Application Dilution
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200